Skip to main content

Conference Correspondent

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Outcomes of Ibrutinib Therapy by Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL

Conference Correspondent

A Diagnostic Test for Lupus Based on DNA Methylation Signatures from Peripheral Blood Mononuclear Cells

Conference Correspondent

The Epidemiology of Systemic Lupus Erythematosus: Disease Prevalence and Impact on Employment and Work Productivity

Conference Correspondent

Pregnancy Complications in Lupus: Retrospective Observational Analysis from a US Health Claims Database

Conference Correspondent

Effects of Blisibimod on Renal and Inflammation Biomarkers and on Serum Immunoglobulin and Infection Risk in Patients with Lupus: Results from the PEARL-SC and Open-Label Extension Studies

Conference Correspondent

Safety and Efficacy of Epratuzumab in Patients with Lupus Confirmed in a Long-Term Open-Label Extension Study

4
5
6
7
8

Page 7 of 8
Results 61 - 70 of 80